Tenax Therapeutics released its corporate presentation for October 2026 following the failure of the Phase 3 LEVEL trial to meet its primary endpoint. A new study, LEVEL-2, was announced to further evaluate oral levosimendan, though this update comes with forward-looking statement risks.